ArticleScientific reports2025
Relationship between serum mature brain-derived neurotrophic factor level and coronary slow flow phenomenon: a cross-sectional study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Admission Serum Total Brain-Derived Neurotrophic Factor and Angiographic No-Reflow in Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.Medicina (Kaunas, Lithuania) · 2026Observational
- Brain-Derived Neurotrophic Factor in Acute Coronary Syndromes: Beyond Diagnosis Toward Biological Phenotyping and Risk Stratification.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain-derived neurotrophic factor (BDNF) has been implicated in cardiovascular disease. However, the role of BDNF in coronary slow flow phenomenon (CSFP) remains unclear. This study explored the relationship between serum mature BDNF (mBDNF) levels and thrombolysis-in-myocardial-infarction frame count (TFC) as a measure of CSFP. Serum mBDNF was measured in 125 patients (mean age 60.2 years, 57% women) with suspected coronary artery disease before undergoing coronary angiography. Based on the corrected TFC, 77 patients were categorized as having CSFP and 48 normal coronary flow (NCF). The relationship of mTFC (mTFC) and CSFP with serum mBDNF was analysed using multivariable linear and logistic regression. mTFC ranged from 15.9 to 68.5 and mBDNF from 13.2 to 60.6 ng/mL. Serum mBDNF was inversely correlated with mTFC (Spearman rho - 0.327, P < 0.001) and reduced in CSFP (median 25.9 ng/mL IQR 20.6, 32.2 vs. 34.5 ng/mL IQR 27.4, 41.6, P < 0.001). Multivariable linear and logistic regression analyses indicated that log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.